| P50 | author | Pierce Chow | Q43282371 |
| | Po-Chin Liang | Q57148109 |
| P2093 | author name string | David Chee Eng Ng | |
| | Richard Hoau Gong Lo | |
| | Rheun-Chuan Lee | |
| | Wan Yee Lau | |
| | Apoorva Gogna | |
| | Farah Gillan Irani | |
| | Khin Maung Win | |
| | David Wai Meng Tai | |
| | Kieron Boon Leng Lim | |
| | Ramon S Santos-Ocampo | |
| | Vanessa H de Villa | |
| | Yee Leong Teoh | |
| | Yun Hwan Joseph Kim | |
| P2860 | cites work | Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation | Q26852105 |
| | Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives | Q27023616 |
| | Management of hepatocellular carcinoma: An update | Q27860530 |
| | EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study | Q33691454 |
| | Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials | Q34068152 |
| | Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma | Q34089023 |
| | Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis | Q34155198 |
| | Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis | Q34585175 |
| | Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis | Q34621197 |
| | Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34664272 |
| | When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations | Q34702055 |
| | Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis | Q34874473 |
| | Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 |
| | Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma | Q35085486 |
| | Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers | Q35979752 |
| | Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications | Q36287668 |
| | Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. | Q36673829 |
| | Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. | Q37376714 |
| | Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. | Q38101443 |
| | Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience | Q38155625 |
| | The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. | Q38228205 |
| | Treatment of intermediate-stage hepatocellular carcinoma | Q38236876 |
| | The role of bridge therapy prior to orthotopic liver transplantation | Q38237526 |
| | Yttrium-90 radioembolization of hepatic metastases from colorectal cancer | Q38239688 |
| | Hepatic radioembolization as a bridge to liver surgery. | Q38240151 |
| | Downstaging hepatocellular carcinoma: A systematic review and pooled analysis | Q38484928 |
| | In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 |
| | Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. | Q39310997 |
| | A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma | Q39905453 |
| | Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. | Q40705749 |
| | Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK. | Q40975772 |
| | Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation | Q42601023 |
| | Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus | Q42726305 |
| | Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. | Q43817879 |
| | Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer | Q43885252 |
| | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial | Q44089673 |
| | Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? | Q44126350 |
| | Patient Selection and Activity Planning Guide for Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres | Q44692003 |
| | Radioembolization using yttrium-90 microspheres as bridging and downstaging treatment for unresectable hepatocellular carcinoma before liver transplantation: initial single-center experience | Q46193138 |
| | Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. | Q50535030 |
| | Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. | Q50868783 |
| | Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. | Q51021204 |
| | Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. | Q51063336 |
| | Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 |
| | Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. | Q51873576 |
| | Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. | Q53525194 |
| | Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis | Q56970979 |
| | Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience | Q56989067 |
| | Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study | Q57763422 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1193-1204 | |
| P577 | publication date | 2016-03-23 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Current role of selective internal radiation with yttrium-90 in liver tumors | |
| P478 | volume | 12 | |